STOCK TITAN

Annovis Bio, Inc. - ANVS STOCK NEWS

Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.

Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage pharmaceutical company dedicated to developing novel therapies for neurodegenerative diseases such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Headquartered in Malvern, Pennsylvania, Annovis is pioneering innovative approaches to combat neurodegeneration by targeting multiple neurotoxic proteins simultaneously. The company’s lead compound, Buntanetap (formerly Posiphen or ANVS401), is designed to inhibit the formation of amyloid beta, tau, alpha-synuclein, and TDP43, aiming to improve synaptic transmission and axonal transport while reducing neuroinflammation.

Annovis Bio’s flagship product, Buntanetap, is in phase II/III clinical trials for the treatment of mild to moderate AD and early PD. The drug has shown promising results, demonstrating significant improvements in cognitive function and reducing neurotoxic biomarkers in patients. Alongside Buntanetap, the company is advancing ANVS405 for acute neurodegeneration post-traumatic brain injury and stroke, and ANVS301, currently in phase I trials, aimed at enhancing cognitive capabilities in advanced AD and dementia.

Founded in 2008 by Dr. Maria Maccecchini, Ph.D., Annovis Bio continues to focus on restoring brain function to alleviate symptoms and improve the quality of life for individuals affected by neurodegenerative diseases. The company has established itself as a leader in the field through partnerships, rigorous scientific research, and a commitment to transparency with all stakeholders.

Recent achievements include the completion of a Phase II/III study of Buntanetap in Alzheimer’s patients, demonstrating a statistically significant improvement in cognition and a favorable safety profile. Additionally, Annovis has filed a patent application for the use of Buntanetap in treating neuropsychiatric conditions such as autism and bipolar disorder, highlighting the drug’s versatile potential.

A financial overview reveals that Annovis ended the first quarter of 2024 with $3.1 million in cash, ensuring operational sustainability into the fourth quarter through strategic financial management. The company has actively engaged with the scientific and investment communities, participating in notable conferences like the International Conference on Alzheimer’s and Parkinson’s Diseases and hosting investor calls to discuss clinical milestones and future plans.

For more information about Annovis Bio, visit their website and follow them on LinkedIn and X (formerly Twitter).

Rhea-AI Summary

On March 11, 2021, Annovis Bio, ANVS, announced that Dr. Maria Maccecchini, its Founder and CEO, will attend the Q1 Virtual Investor Summit from March 23-25, 2021. Dr. Maccecchini's presentation is scheduled for March 24 at 11:30 AM ET. The summit aims to connect smallcap and microcap companies with investors, featuring 100 companies and over 300 participants.

For registration details, visit www.investorsummitgroup.com. Annovis focuses on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.61%
Tags
conferences
-
Rhea-AI Summary

On February 16, 2021, Annovis Bio (NYSE: ANVS), a clinical-stage company focused on treatments for neurodegenerative diseases, announced that Dr. Maria Maccecchini will present at the BIO CEO & Digital Conference from February 16-18. The presentation will be available on demand for registered attendees. Annovis Bio aims to address Alzheimer's disease, Parkinson's disease, and Alzheimer’s in Down Syndrome by developing a unique drug that targets multiple neurotoxic proteins, improving nerve cell function. The company is conducting two Phase 2a trials on patients with AD and PD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.98%
Tags
conferences
-
Rhea-AI Summary

On December 17, 2020, Annovis Bio (NYSE American: ANVS) announced that CEO Maria Maccecchini, Ph.D., will be featured in an interview on The RedChip Money Report. The program reaches 100 million homes across Europe and airs on Sundays at 6 p.m. local time on Bloomberg International. In the interview, Maccecchini discusses Annovis' innovative approach to treating Alzheimer’s disease (AD) and other neurodegenerative diseases, the ongoing clinical trials, and anticipated milestones. Annovis is developing a drug aimed at improving nerve cell function affected by neurotoxic proteins.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
none
Rhea-AI Summary

Annovis Bio (NYSE American: ANVS) announced a presentation by CEO Dr. Maria Maccecchini at the NYAS Virtual Conference on December 4, 2020, focusing on tackling neurodegeneration in Alzheimer’s, Parkinson’s, and Down syndrome. The lead candidate, ANVS401, showed promise by lowering neurotoxic proteins, thereby restoring axonal transport and nerve cell health. Current Phase 2a studies aim to assess the drug's effectiveness, with preliminary results expected in Q1 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
Rhea-AI Summary

On December 8, 2020, Annovis Bio (NYSE American: ANVS) CEO, Maria Maccecchini, Ph.D., will present at Benzinga's inaugural Global SmallCap Conference at 4:30 pm ET. The presentation will cover the company's innovative approach to Alzheimer's disease (AD), Parkinson's disease (PD), and its current clinical pipeline. Notably, Annovis is conducting ongoing Phase 2a studies for AD and PD, with upcoming data publications expected. Investors can register for free access to the virtual conference taking place from December 8-9, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
conferences
-
Rhea-AI Summary

Annovis Bio (NYSE American: ANVS), a clinical-stage company focused on neurodegenerative diseases, announces that CEO Maria Maccecchini will present at the New York Academy of Sciences’ virtual conference on December 4, 2020. Her presentation will cover the company's lead candidate, ANVS401, which aims to lower neurotoxic proteins linked to Alzheimer’s and Parkinson’s diseases. Annovis is currently conducting two Phase 2a studies, expecting preliminary results in early 2021, showcasing its unique approach to neurodegeneration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.52%
Tags
conferences
Rhea-AI Summary

On November 16, 2020, Annovis Bio (NYSE American: ANVS) announced its participation in the A.G.P. Virtual Healthcare Symposium scheduled for November 19, 2020. CEO Maria Maccecchini, Ph.D., and CFO Jeff McGroarty, MBA, CPA, will host one-on-one meetings with investors to discuss the company's development pipeline and milestones. Annovis is focused on treating neurodegenerative diseases, including Alzheimer's, Parkinson's, and Alzheimer's in Down Syndrome, with ongoing Phase 2a studies aimed at improving memory and function. Interested investors can register for meetings through A.G.P.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
conferences
-
Rhea-AI Summary

On November 12, 2020, Annovis Bio Inc. (ANVS) announced the successful completion of its dog cohort in a chronic toxicology study for its lead compound, ANVS401, aimed at treating Alzheimer’s and Parkinson’s diseases. Funded by a $1.9 million NIH grant, the nine-month study reported no negative side effects, reinforcing previous positive safety findings. CEO Maria Maccecchini highlighted this as a crucial milestone for enabling long-term human trials, with interim data from ongoing Phase 2a trials expected in Q1 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
Rhea-AI Summary

Annovis Bio Inc. (NYSE American: ANVS) announced that its CEO, Dr. Maria Maccecchini, will present at the Meridian Clinical Trials Summit on November 2, 2020. Her presentation will focus on strategies for de-risking Phase 3 clinical studies using insights from ongoing Phase 2a trials for Alzheimer's and Parkinson's diseases. Dr. Maccecchini aims to demonstrate how the lead compound, ANVS401, can potentially reverse toxic neural effects and restore brain function. The company is developing therapies targeting multiple neurotoxic proteins to improve cognitive and bodily functions affected by these diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.39%
Tags
conferences clinical trial
Rhea-AI Summary

On October 29, 2020, Annovis Bio (NYSE American: ANVS) announced the resumption of its Phase 2a clinical trial for ANVS401, targeting early Alzheimer's disease (AD) patients. This follows a suspension due to COVID-19 in March 2020. The trial includes 24 participants across six U.S. sites, with 15 patients already treated. Data is anticipated in 2021. CEO Maria Maccecchini expressed optimism about the drug's ability to enhance axonal transport and improve cognitive function, despite pandemic-related delays in broader clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
clinical trial covid-19

FAQ

What is the current stock price of Annovis Bio (ANVS)?

The current stock price of Annovis Bio (ANVS) is $5.01 as of December 24, 2024.

What is the market cap of Annovis Bio (ANVS)?

The market cap of Annovis Bio (ANVS) is approximately 69.1M.

What is Annovis Bio, Inc.?

Annovis Bio, Inc. is a clinical-stage pharmaceutical company focused on developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's.

What is Buntanetap?

Buntanetap is Annovis Bio's leading drug candidate designed to inhibit multiple neurotoxic proteins, aiming to improve cognitive function in patients with neurodegenerative diseases.

Where is Annovis Bio headquartered?

Annovis Bio is headquartered in Malvern, Pennsylvania.

Who founded Annovis Bio?

Annovis Bio was founded by Dr. Maria Maccecchini, Ph.D., in 2008.

What are the key focus areas for Annovis Bio?

Annovis Bio focuses on developing drugs for Alzheimer’s Disease, Parkinson’s Disease, traumatic brain injury, stroke, and other neurodegenerative conditions.

What recent achievements has Annovis Bio accomplished?

Recent achievements include the completion of a Phase II/III study of Buntanetap in Alzheimer’s patients and the filing of a patent application for its use in treating neuropsychiatric conditions.

What are the financial highlights for Annovis Bio?

As of the first quarter of 2024, Annovis Bio reported $3.1 million in cash and continues to effectively manage its financial resources.

What is ANVS405?

ANVS405 is a drug in development by Annovis Bio for protecting the brain after traumatic brain injury and stroke.

What is ANVS301?

ANVS301 is an Annovis Bio drug in phase I clinical trials aimed at increasing cognitive capability in advanced stages of Alzheimer's Disease and dementia.

How can I learn more about Annovis Bio's developments?

For more information, visit Annovis Bio's official website at www.annovisbio.com and follow them on LinkedIn and X (formerly known as Twitter).

Annovis Bio, Inc.

NYSE:ANVS

ANVS Rankings

ANVS Stock Data

69.12M
10.98M
20.4%
8.83%
10.1%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MALVERN